These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22972180)

  • 21. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Maeda H; Kubota A; Tanaka Y; Terauchi Y; Matsuba I;
    Diabetes Res Clin Pract; 2012 Jan; 95(1):e20-2. PubMed ID: 22055835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
    Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
    Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
    Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
    Maeda H; Kubota A; Kanamori A; Tanaka Y; Terauchi Y; Matsuba I;
    J Endocrinol Invest; 2013 Sep; 36(8):568-73. PubMed ID: 23385888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
    Umpierrez GE; Gianchandani R; Smiley D; Jacobs S; Wesorick DH; Newton C; Farrokhi F; Peng L; Reyes D; Lathkar-Pradhan S; Pasquel F
    Diabetes Care; 2013 Nov; 36(11):3430-5. PubMed ID: 23877988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
    Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.
    Nonaka K; Kakikawa T; Sato A; Okuyama K; Fujimoto G; Kato N; Suzuki H; Hirayama Y; Ahmed T; Davies MJ; Stein PP
    Diabetes Res Clin Pract; 2008 Feb; 79(2):291-8. PubMed ID: 17933414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G; Ragonesi PD; Fogari E; Cicero AF; Bianchi L; Bonaventura A; Romano D; Maffioli P
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
    Takahara M; Shiraiwa T; Kaneto H; Katakami N; Matsuoka TA; Shimomura I
    Endocr J; 2012; 59(12):1131-6. PubMed ID: 22850206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
    Iwamoto Y; Tajima N; Kadowaki T; Nonaka K; Taniguchi T; Nishii M; Arjona Ferreira JC; Amatruda JM
    Diabetes Obes Metab; 2010 Jul; 12(7):613-22. PubMed ID: 20590736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
    Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
    Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
    Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
    Aschner P; Chan J; Owens DR; Picard S; Wang E; Dain MP; Pilorget V; Echtay A; Fonseca V;
    Lancet; 2012 Jun; 379(9833):2262-9. PubMed ID: 22683131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study.
    Takai M; Ishikawa M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
    Diabetes Res Clin Pract; 2014 Mar; 103(3):e30-3. PubMed ID: 24525293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.